RBF Capital’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

RBF Capital’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-68,034	Closed	-$219K	–	558
2022 Q1	$219K	Hold	68,034	–	–	0.01%	466
2021 Q4	$195K	Sell	68,034 -800	-1%	-$2.98K	0.01%	485
2021 Q3	$273K	Hold	68,834	–	–	0.02%	414
2021 Q2	$410K	Buy	+68,834	New	+$487K	0.02%	375

RBF Capital's CMPI Position: Q2 2022 in Review

RBF Capital sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 68,034 shares — an estimated $219K sold.

RBF Capital first reported a position in CMPI in Q2 2021 and held it in 4 quarters. The position peaked at $410K in Q2 2021. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

RBF Capital reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RBF Capital sold 68,034 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $219K.
RBF Capital first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
RBF Capital's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $410K in Q2 2021.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on RBF Capital's 13F filing for Q2 2022, filed 15 Aug 2022.